Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Arne Scheu, Irsyad Khairil · 2 co-founders
Profile coverage4 of 8 · missing Funding, Signals, Customers, Stack / tools · last run 8/11/2026
About
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.